American Gene Technologies Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 45
Employees
  • Latest Deal Type
  • Series E2
  • Latest Deal Amount
  • $30M
Latest Deal Amount
  • Investors
  • 6

American Gene Technologies General Information

Description

Developer of proprietary gene-delivery platform for the rapid development of cell and gene therapies intended to cure infectious diseases, cancers, and inherited disorders. The company's gene and cell therapy platform has three patents for the technology used to make the AGT103-T cell product to functionally cure HIV+ individuals, and ten patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to eliminate a variety of human solid tumors, such as breast, prostate, and liver cancer. And has developed a synthetic gene for treating Phenylketonuria (PKU), enabling physicians to get effective drugs to treat patients. lketonuria (PKU), enabling physicians to get effective drugs to treat patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 9713 Key West Avenue
  • 5th Floor
  • Rockville, MD 20850
  • United States
+1 (301) 000-0000

American Gene Technologies Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

American Gene Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series E2) 14-Mar-2021 $30M 0000 Completed Generating Revenue
9. Later Stage VC (Series E1) 14-Feb-2019 0000 0000 00000 Completed Clinical Trials - Phase 1
8. Angel (individual) 01-Sep-2020 0000 Completed Generating Revenue
7. Debt - PPP 13-Apr-2020 00000 0000 Completed Generating Revenue
6. Later Stage VC (Series D1) 30-Nov-2018 000.00 0000 00000 Completed Generating Revenue
5. Later Stage VC (Series C1) 26-Apr-2016 00.00 00.00 000.00 Completed Generating Revenue
4. Angel (individual) 30-Apr-2015 00.00 00.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2015 00000 000 Completed Generating Revenue
2. Angel (individual) 03-Sep-2013 $1M $1M 000 Completed Pre-Clinical Trials
1. Grant 01-Apr-2012 $1.2M Completed Generating Revenue
To view American Gene Technologies’s complete valuation and funding history, request access »

American Gene Technologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E1 0,000,000 00.000000 00.0 00 00 00 00 0.000
Series D1 0,000,000 00.000000 00.00 00 00 00 00 0.000
Series C1 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 0.000
Series B1 4,166,666 $0.000100 $0.04 $0.48 $0.48 1x $0.48 7.86%
Series A1 2,170,610 $0.000100 $0.04 $0.46 $0.46 1x $0.46 4.1%
To view American Gene Technologies’s complete cap table history, request access »

American Gene Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of proprietary gene-delivery platform for the rapid development of cell and gene therapies intended to cure in
Drug Discovery
Rockville, MD
45 As of 2021
0000
00000000000 0000

0000000

m ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

00000000

oluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pr
0000000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

American Gene Technologies Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avrobio Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
00000000 000000000 Formerly PE-Backed San Rafael, CA 0000 00000 0000 00000
To view American Gene Technologies’s complete competitors history, request access »

American Gene Technologies Executive Team (9)

Name Title Board Seat Contact Info
Jeffrey Galvin Co-Founder, Chief Executive Officer & Board Member
Neil Lyons Chief Financial Officer & Executive Vice President
David Pauza Ph.D Chief Science Officer
Norman Rogers Executive, Business Development
You’re viewing 4 of 9 executive team members. Get the full list »

American Gene Technologies Board Members (6)

Name Representing Role Since
Aaron Galvin American Gene Technologies Board Member 000 0000
Jeffrey Galvin American Gene Technologies Co-Founder, Chief Executive Officer & Board Member 000 0000
Julia Brown Self Board Member 000 0000
Qi Tang American Gene Technologies Board Member 000 0000
Tommy Thompson JD Self Board Member & Advisor 000 0000
You’re viewing 5 of 6 board members. Get the full list »

American Gene Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

American Gene Technologies Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
10X Capital Venture Capital Minority 000 0000 000000 0
Lyle Berkowitz Angel (individual) Minority 000 0000 000000 0
Gaingels Venture Capital Minority 000 0000 000000 0
Alumni Ventures Group Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »